Catalyst Pharmaceuticals

Catalyst Pharmaceuticals(CPRX)

CORAL GABLES, FL
Pharmaceutical1 H-1B visas (FY2023)

Focus: Small Molecules for Addiction Treatment

Catalyst Pharmaceuticals is a life sciences company focused on Small Molecules for Addiction Treatment.

Neurology
Funding Stage
PUBLIC
Open Jobs
4

Products & Portfolio (4)

Pipeline & Clinical Trials

Hexaminolevulinate hydrochloride
Bladder Cancer
N/A
Clinical Trials (1)
NCT02660645Blue Light Cystoscopy With Cysview® Registry
N/A
Clinical Trials (1)
NCT05072912Screening Study to Identify Patients With Complement Factor I Deficiencies
N/A
Clinical Trials (1)
NCT04019795Modulated Light Therapy in Participants With Pattern Hair Loss
N/A
Clinical Trials (1)
NCT02857972Proof Of Concept Menstrual Hygiene Product-Wondaleaf®
N/A
Clinical Trials (1)
NCT06564974Registry Study to Observe Long-term Safety of Vamorolone (AGAMREE®) in Patients With Duchenne Muscular Dystrophy-SUMMIT
N/A
bilateral ultrasound-guided rectus sheath block
Pediatric Postoperative Pain
N/A
Clinical Trials (1)
NCT01015053Postoperative Pain After Pediatric Umbilical Hernia Repair
N/A
Wondaleaf®
Pregnancy
N/A
Clinical Trials (1)
NCT02593214Performance and Safety Trial of an Innovative Female Condom (Wondaleaf®)
N/A
Catalyst CSR Total Shoulder System
Osteoarthritis Shoulder
N/A
N/A
Clinical Trials (1)
NCT03062631Treatment Use of 3,4 Diaminopyridine in Congenital Myasthenia
N/A
Standard of Care plus Enhanced Patient Education
Aortic Valve Disease
N/A
Clinical Trials (1)
NCT06106451Optimization Post-TAVR to IMprove Activity Levels (OPTIMAL Study)
N/A
A Pilot Functional Performances Study of Two Synthetic Male Condom
Functional Performance
N/A
Clinical Trials (1)
NCT03324594A Pilot Functional Performances Study of Two Synthetic Male Condom
N/A
Amifampridine Phosphate
Congenital Myasthenic Syndrome
N/A
Clinical Trials (1)
NCT02189720Expanded Access Study Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS),Congenital Myasthenic Syndrome
N/A
N/A
Clinical Trials (1)
NCT05569551Umbilical Cord Care in Term Neonates: The Role of Wondaleaf Adhesive Pouch (WLAP)
N/A
Narrative Medicine Journaling Intervention
DSD
N/A
Clinical Trials (1)
NCT06989593Breaking Silence Through Story: A Narrative Medicine Intervention for Parents of Children With Urogenital Conditions
N/A
Clinical Trials (1)
NCT05095623A Natural History Study to Assess the Clinical Outcomes of Patients With Complement Factor I Deficiency-Mediated Disease
N/A
Clinical Trials (1)
NCT04339296Connected Healthcare for Individuals Living at Home With Chronic Conditions
N/A
Phase 1
Clinical Trials (1)
NCT04072237Study of Coagulation Faction VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia
Phase 1
Phase 1
Clinical Trials (1)
NCT01493596A Safety, Tolerability and Pharmacokinetic Study of CPP-115
Phase 1
PF-05280602
Hemophilia A
Phase 1
Clinical Trials (1)
NCT01439971Phase 1 Safety, Pharmacokinetics And Pharmacodynamics Study Of Recombinant Factor VIIa Variant (813d) In Adult Subjects With Hemophilia
Phase 1
Bumetanide
Seizures
Phase 1
Clinical Trials (1)
NCT00830531Pilot Study of Bumetanide for Newborn Seizures
Phase 1
Airway Bypass
Emphysema or COPD
Phase 1
Clinical Trials (1)
NCT06249529Airway Bypass - Safety and Feasibility Study
Phase 1
ISU304/CB2679d/Dalcinonacog alfa 75~150 IU/kg
Hemophilia B
Phase 1
Clinical Trials (1)
NCT03186677Dose-escalation Study to Investigate the Safety, PK, and PD of ISU304/CB2679d in Hemophilia B Patients
Phase 1
Coagulation Factor VIIa variant
Factor VII Deficiency
Phase 1/2
Clinical Trials (1)
NCT04548791Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Inherited Bleeding Disorders
Phase 1/2
Phase 2
Clinical Trials (1)
NCT00611130Vigabatrin for Treatment of Cocaine Dependence
Phase 2
Amifampridine Phosphate
Muscular Atrophy, Spinal
Phase 2
Clinical Trials (1)
NCT03781479Controlled Trial to Evaluate Amifampridine Phosphate in Spinal Muscular Atrophy Type 3 Patients
Phase 2
Clinical Trials (1)
NCT05556824Multi-Center Study of Panosyl-Isomaltooligosaccharides Adjunctive to PPI Therapy to Treat GERD
Phase 2
Coagulation Factor IX variant
Hemophilia B
Phase 2
Clinical Trials (1)
NCT03995784Study of Next-Generation Recombinant Factor IX Variant in Adult Subjects With Hemophilia B
Phase 2
Phase 2
Clinical Trials (1)
NCT00527683Double Blind Study of Vigabatrin for the Treatment of Cocaine Dependence
Phase 2
Coagulation Factor VIIa variant
Hemophilia A With Inhibitor
Phase 2
Clinical Trials (1)
NCT03407651Study of Coagulation Factor VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia A and B
Phase 2
Amifampridine Phosphate 10 MG Oral Tablet
Spinal Muscular Atrophy Type 3
Phase 2
Clinical Trials (1)
NCT03819660Long Term Safety of Amifampridine Phosphate in Spinal Muscular Atrophy 3
Phase 2
Dupilumab
COVID-19
Phase 2
Clinical Trials (1)
NCT04920916Safety and Efficacy of Dupilumab for Treatment of Hospitalized COVID-19 Patients
Phase 2
Phase 2
Clinical Trials (1)
NCT05796570A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid Malignancies
Phase 2
CPP-109 vigabatrin
Methamphetamine Dependence
Phase 2
Clinical Trials (1)
NCT00730522Safety and Efficacy Study of Vigabatrin to Treat Methamphetamine Dependence
Phase 2
Phase 2/3
Clinical Trials (1)
NCT01281202Vigabatrin for the Treatment of Cocaine Dependency
Phase 2/3
Amifampridine Phosphate
Lambert Eaton Myasthenic Syndrome
Phase 3
Clinical Trials (1)
NCT01377922A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)
Phase 3
amifampridine phosphate
Myasthenic Syndromes, Congenital
Phase 3
Clinical Trials (1)
NCT02562066Amifampridine Phosphate for the Treatment of Congenital Myasthenic Syndromes
Phase 3
Clinical Trials (1)
NCT04489537Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Hemophilia A or B
Phase 3
Amifampridine Phosphate
Myasthenia Gravis, Generalized
Phase 3
Clinical Trials (1)
NCT03304054Study to Evaluate Amifampridine Phosphate in Patients With MuSK-MG
Phase 3
Phase 3
Clinical Trials (1)
NCT05094401Use of an Investigational Digital Therapeutic in Patients With Type 2 Diabetes
Phase 3
Amifampridine Phosphate
Lambert-Eaton Myasthenic Syndrome
Phase 3
Clinical Trials (1)
NCT02970162Phase 3 Study to Evaluate Efficacy of Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS)
Phase 3
Amifampridine Phosphate
Myasthenia Gravis, MuSK
Phase 3
Clinical Trials (1)
NCT03579966Long Term Safety Study of Amifampridine Phosphate in MuSK-MG (Muscle Specific Tyrosine Kinase Myasthenia Gravis)
Phase 3

Open Jobs (4)

Interview Prep Quick Facts
Portfolio: 4 approved products, 40 clinical trials
Top TAs: Neurology, Rare Diseases
H-1B (2023): 1 approval
SEC Filings: 2 available
Open Roles: 4 active jobs
Portfolio Health
Growth1 (25%)
Peak1 (25%)
LOE Approaching2 (50%)
4 total products
Therapeutic Area Focus
Neurology
2 marketed
Rare Diseases
1 marketed
Marketed
Pipeline

Financials (FY2025)

Revenue
$398M86%
R&D Spend
$93M(23%)371%
Net Income
$71M
Cash
$518M

Hiring Trend

Stable
4
Open Roles
+0
Added
-0
Filled/Removed

Based on last 4 crawl cycles

Visa Sponsorship

Sponsors Work Visas
H-1B Petitions (FY2023)
1
Approved
0
Denied
100%
Rate

Source: USCIS H-1B Employer Data Hub